212 related articles for article (PubMed ID: 29040431)
1. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate.
Pore SK; Hahm ER; Latoche JD; Anderson CJ; Shuai Y; Singh SV
Carcinogenesis; 2018 Feb; 39(2):134-145. PubMed ID: 29040431
[TBL] [Abstract][Full Text] [Related]
2. A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption.
Pore SK; Hahm ER; Kim SH; Singh KB; Nyiranshuti L; Latoche JD; Anderson CJ; Adamik J; Galson DL; Weiss KR; Watters RJ; Lee B; Kumta PN; Singh SV
Mol Cancer Ther; 2020 Feb; 19(2):420-431. PubMed ID: 31784454
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation.
Hahm ER; Kim SH; Pore SK; Mathan SV; Singh RP; Singh SV
Mol Carcinog; 2024 Feb; 63(2):301-313. PubMed ID: 37921547
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
5. Germacrone alleviates breast cancer-associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF-κB signaling pathways.
Lin Z; Yang Y; Liu T; Wu Z; Zhang X; Yang J
Phytother Res; 2024 Jun; 38(6):2860-2874. PubMed ID: 38558446
[TBL] [Abstract][Full Text] [Related]
6. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I; Luo KW; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ko CH; Yue GG; Lau CB; Ingman W; Ponomarev V; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Int J Oncol; 2014 Aug; 45(2):532-40. PubMed ID: 24865346
[TBL] [Abstract][Full Text] [Related]
9. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
10. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mitochondrial fusion is an early and critical event in breast cancer cell apoptosis by dietary chemopreventative benzyl isothiocyanate.
Sehrawat A; Croix CS; Baty CJ; Watkins S; Tailor D; Singh RP; Singh SV
Mitochondrion; 2016 Sep; 30():67-77. PubMed ID: 27374852
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
13. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
14. Role of Krüppel-like Factor 4-p21
Kim SH; Singh SV
Cancer Prev Res (Phila); 2019 Mar; 12(3):125-134. PubMed ID: 30723175
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
[TBL] [Abstract][Full Text] [Related]
16. Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells in vitro and in vivo.
Kim SH; Sehrawat A; Singh SV
Cancer Prev Res (Phila); 2013 Aug; 6(8):782-90. PubMed ID: 23661606
[TBL] [Abstract][Full Text] [Related]
17. AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells.
Roy R; Hahm ER; White AG; Anderson CJ; Singh SV
Mol Carcinog; 2019 Jun; 58(6):996-1007. PubMed ID: 30720225
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
20. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3.
Kim SH; Nagalingam A; Saxena NK; Singh SV; Sharma D
Carcinogenesis; 2011 Mar; 32(3):359-67. PubMed ID: 21163886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
